Goldsmith DJ. Pro: Should we correct vitamin D deficiency/insufficiency in chronic kidney disease patients with inactive forms of vitamin D or just treat them with active vitamin D forms? Nephrol Dial Transplant 2016; 31:698–705.

• PubMed
Goldsmith DJ. Pro: Should we correct vitamin D deficiency/insufficiency in chronic kidney disease patients with inactive forms of vitamin D or just treat them with active vitamin D forms? Nephrol Dial Transplant 2016; 31:698–705.)| false
• Search Google Scholar
• Export Citation

Goldsmith D, et al.. Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrol Dial Transplant 2015; 30:698–700.

• PubMed
Goldsmith D, . Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrol Dial Transplant 2015; 30:698–700.)| false
• Search Google Scholar
• Export Citation

Pfeffer MA, et al.. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361:2019–2032.

• PubMed
Pfeffer MA, . A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361:2019–2032.)| false
• Search Google Scholar
• Export Citation

EVOLVE Trial Investigators , et al.. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367:2482–2494.

• PubMed
EVOLVE Trial Investigators, . Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367:2482–2494.)| false
• Search Google Scholar
• Export Citation

Cunningham J, et al.. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68:1793–1800.

• PubMed
Cunningham J, . Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68:1793–1800.)| false
• Search Google Scholar
• Export Citation

Parfrey PS, et al.. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: The EVOLVE trial. J Clin Endocrinol Metab 2013; 98:4834–4844.

• PubMed
Parfrey PS, . The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: The EVOLVE trial. J Clin Endocrinol Metab 2013; 98:4834–4844.)| false
• Search Google Scholar
• Export Citation

Reams BD, et al.. Dynamics of cinacalcet use and biochemical control in hemodialysis patients: A retrospective new-user cohort design. BMC Nephrol 2015; 16:175.

• PubMed
Reams BD, . Dynamics of cinacalcet use and biochemical control in hemodialysis patients: A retrospective new-user cohort design. BMC Nephrol 2015; 16:175.)| false
• Search Google Scholar
• Export Citation

Evenepoel P, et al.. A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism. Am J Transplant 2014; 14:2545–2555.

• PubMed
Evenepoel P, . A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism. Am J Transplant 2014; 14:2545–2555.)| false
• Search Google Scholar
• Export Citation